Authors

Claire Crowley, RN, Memorial Sloan Kettering Cancer Center

Latest:

Clinical Oncology in the 21st Century: Reflections on how Healthcare Providers Should Manage Their Public Personas on Social Media

It is important that clinicians engage with social media, since reputations are at risk by not knowing what is being said, shared, and discussed online about them online.

Claire Harrison, MD

Latest:

Ruxolitinib Versus Best Available Therapy for Polycythaemia Vera Intolerant or Resistant to Hydroxycarbamide in a Randomised Trial

Claire Harrison, MD, reviews the use of ruxolitinib in patients who are ineligible for hydroxycarbamide for the management of polycythemia vera (PV).

Claire Manuszak, BS

Latest:

Phase I Study With Prexasertib and LY3300054 in Ovarian Cancer

Claire Manuszak, BS, discusses a phase I study (NCT03495323) with prexasertib (LY2606368) and LY3300054 in ovarian cancer.

Claire Verschraegen, MD

Latest:

Dr Verschraegen on Toxicities Associated with Single-agent vs Doublet Immunotherapy in Melanoma

Claire F. Verschraegen, MD, discusses adverse effects that are commonly associated with the use of single-agent nivolumab vs the combination of ipilimumab plus nivolumab in melanoma.

Clancy Clark, MD

Latest:

Advances in the Management of Hepatic and Pancreatic Malignancies

Perry Shen, MD, FACS, and Clancy Clark, MD, from Wake Forest Baptist Health Comprehensive Cancer Center, discuss advances in the management of hepatic and pancreatic malignancies.

Clara Hwang, MD

Latest:

Dr Hwang on Considering AEs Associated With FDA-Approved Agents in Nonmetastatic Prostate Cancer

Clara Hwang, MD, discusses adverse effects associated with FDA-approved agents for patients with nonmetastatic prostate cancer.

Clarke A. Low, MD

Latest:

Dr. Low on Osimertinib Versus Dacomitinib in EGFR-Mutant NSCLC

Clarke A. Low, MD, discusses osimertinib (Tagrisso) versus dacomitinib (Vizimpro) in EGFR-mutant non–small cell lung cancer.

Claud Grigg, MD

Latest:

Dr. Grigg Discusses CABOSUN Trial in mRCC

Claud Grigg, MD, medical oncologist, Levine Cancer Institute, Atrium Health, discusses the design and results of the CABOSUN trial in metastatic renal cell carcinoma.

Claud M. Grigg Jr, MD

Latest:

Dr. Grigg on the Results of the CheckMate-214 Trial in RCC

Claud M. Grigg, Jr., MD, discusses the results of the CheckMate-214 trial in renal cell carcinoma.

Claude Denham, MD

Latest:

Dr. Denham on Hyperprogression in Patients With NSCLC

Claude Denham, MD, Baylor Medical Center, discusses the manifestation of hyperprogression in patients with non–small cell lung cancer (NSCLC) who have been treated with immunotherapy.

Claudia Henschke, MD, PhD

Latest:

Lung Cancer Screening Needs to Remain State-of-the-Art

In CT screening for lung cancer, the regimen of screening is a critical factor in diagnosing lung cancer early while limiting unnecessary tests and invasive procedures.

Claudine Isaacs, MD

Claudine Isaacs, MD is Professor of Medicine and Oncology and Associate Director for Clinical Research at the Lombardi Comprehensive Cancer Center.

Latest:

Dr Isaacs on Establishing Consensus on DESTINY-Breast09 Data in HER2+ Metastatic Breast Cancer

Claudine Isaacs, MD, discusses how to integrate data from the phase 3 DESTINY-Breast09 trial into the HER2-positive metastatic breast cancer paradigm.

Claudine Isaacs, MD, Lombardi Comprehensive Cancer Center

Latest:

Decision Factors for SubQ Therapy and Unmet Needs

Claudine J. Isaacs, MD, Lombardi Comprehensive Cancer Center

Claudio Anasetti, MD

Latest:

Dr. Anasetti Discusses the Trade-offs of BMT and PBSC

Dr. Claudio Anasetti from the H. Lee Moffitt Cancer Center Discusses the Trade-offs of BMT and PBSC

Claus-Henning KÃ¶hne, MD, PhD, Klinikum Oldenburg

Clayton S. Lau, MD

Latest:

Dr. Lau on Controversies Surrounding Prostate Cancer Screening

Clayton S. Lau, MD, director, Urologic Oncology, director, Robotic Surgery, Prostate Cancer Surgery, interim chair of Urology, City of Hope, discusses the controversies surrounding prostate cancer screening. Lau spoke on this in an interview during the 2016 OncLive State of the Science Summit on GU Cancer.

Clemens A. Schmitt, MD

Latest:

Dr. Schmitt on a Novel Treatment Approach to Hodgkin Lymphoma

Clemens A. Schmitt, MD, director and professor at Berlin School of Integrative Oncology, discusses a conceptually novel treatment approach to classical Hodgkin lymphoma.

Clemens Krepler, MD

Latest:

Patient-Derived Xenograft (PDX) Models as Avatars for Patient Response to Therapy

The promise of personalized medicine in cancer will only be met once physicians have both the arsenal of therapeutics they need and a more complete understanding of genomic tumor profiles.